Year: 2020
Type: article
Abstract: The coronavirus disease 2019 (COVID-19) pandemic has farreaching ramifications for patients undergoing cancer treatment. Oncologists and institutions have adjusted treatment practices and, in many cases, significantly curtailed clinical trial conduct. Whether these adjustments mitigate the risk of COVID-19 complications without jeopardizing treatment of the cancer is unknown. Given the expected duration of the pandemic, it is imperative that treatment of the patient's cancer remain the priority and that advances in drug development continue through appropriately designed clinical trials.
DOI: 10.1002/cpt.1920
Authors: Sarah A. Holstein, Julie M. Vose
Institution: University of Nebraska Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3031814834